Immunoglobulin, Anti-(Human Cd3 Antigen ?-Chain) (Human-Mus Musculus Single-Chain Fv Fragment Vl-((Ggggs)4Gggs)-Vh) Fusion Protein With Peptide Linker (Ggggs) Fusion Protein With T-Cell Receptor ? Chain [171-Cysteine,189-Alanine,203-Asparatic Acid] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment), Disulfide With T Cell Receptor ? Chain [163-Cysteine] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment)
Melanoma
Explore 435 assets in Melanoma →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Immunocore Ltd
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06112314CT.gov IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin, Anti-(Human Cd3 Antigen ?-Chain) (Human-Mus Musculus Single-Chain Fv Fragment Vl-((Ggggs)4Gggs)-Vh) Fusion Protein With Peptide Linker (Ggggs) Fusion Protein With T-Cell Receptor ? Chain [171-Cysteine,189-Alanine,203-Asparatic Acid] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment), Disulfide With T Cell Receptor ? Chain [163-Cysteine] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment) (this asset) | Immunocore Ltd | P3 | CCC · 54 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin, Anti-(Human Cd3 Antigen ?-Chain) (Human-Mus Musculus Single-Chain Fv Fragment Vl-((Ggggs)4Gggs)-Vh) Fusion Protein With Peptide Linker (Ggggs) Fusion Protein With T-Cell Receptor ? Chain [171-Cysteine,189-Alanine,203-Asparatic Acid] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment), Disulfide With T Cell Receptor ? Chain [163-Cysteine] Anti-(Human Hla-A2 Antigen Complex With Preferentially Expressed Antigen Of Melanoma Protein Peptide) (Human N-Terminal Fragment) in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-anti-human-cd3-antigen-chain-human-mus-musculus-single-chain-fv-fragment-vl-ggggs4gggs-vh-fusion-protein-with-peptide-linker-ggggs-fusion-protein-with-t-cell-receptor-chain-171-cysteine189-alanine203-asparatic-acid-anti-human-hla-a2-antigen-complex-with-preferentially-expressed-antigen-of-melanoma-protein-peptide-human-n-terminal-fragment-disulfide-with-t-cell-receptor-chain-163-cysteine-anti-human-hla-a2-antigen-complex-with-preferentially-expressed-antigen-of-melanoma-protein-peptide-human-n-terminal-fragment-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →